Vanguard Capital Management
HAE icon

Vanguard Capital Management’s Haemonetics HAE Stock Holding History

Vanguard Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$154M Sell
2,059,578
-30,811
-1% -$1.98M ﹤0.01% 1306
2026
Q1 		$118M Buy
+2,090,389
New +$136M ﹤0.01% 1382

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Vanguard Capital Management's HAE Position: Q2 2026 in Review

Vanguard Capital Management reduced its Haemonetics (HAE) stake by 1.5% in Q2 2026, selling an estimated $1.98M and leaving 2,059,578 shares worth $154M. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

Vanguard Capital Management first reported a position in HAE in Q1 2026 and has held it in 2 quarters since. 327 funds tracked by Wall St. Rank hold HAE as of Q2 2026.

  • Vanguard Capital Management held 2,059,578 shares of Haemonetics worth $154M as of Q2 2026.
  • Vanguard Capital Management sold 30,811 Haemonetics shares in Q2 2026, an estimated $1.98M.
  • Haemonetics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1306 holding.
  • Vanguard Capital Management first reported a position in Haemonetics in Q1 2026 and has held it in 2 quarters since.
  • 327 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.